Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CHINARES PHARMA's Innovative Drug BGM0504 for Weight Loss Has NDA Accepted
Recommend 8 Positive 5 Negative 7 |
||||
|
||||
|
CHINARES PHARMA (03320.HK) announced that the new drug application (NDA) for the innovative drug "BGM0504 Injection", jointly developed by its subsidiary China Resources Sanjiu Medical & Pharmaceutical and BrightGene Bio-Medical Technology, for the weight loss indication has been officially accepted by the Center for Drug Evaluation of the National Medical Products Administration. This marks the product's transition from clinical development to the NDA filing stage, taking a critical step toward commercialization. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
